ReNeuron Group plc
("ReNeuron" or "the Company" or "the Group")
Grant of Options
ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that grants were made on 14 July 2022 for options over Ordinary Shares of 1p each ("Options") under the terms of the Company's Long Term Incentive Plan, Consultant Option Agreement (together "The Plans") and its Non-Executive Share Option Scheme. The grants made to Directors and Persons Discharging managerial Responsibilities (PDMRs) are listed below.
The Options granted under The Plans have an exercise price of 31.5 pence per share, being the closing mid-market price of the Company's shares on 13 July 2022. The Options vest in equal proportions at 12, 24 and 36 months from the date of grant. None of the Options are subject to the achievement of performance conditions.
The Options granted to Iain Ross are granted under the Non-Executive Share Option Scheme. The Options are granted with an exercise price of 31.5 pence per share without performance conditions and vest monthly over three years on a straight-line basis.
|
Name |
Title |
Date of grant of Options |
Number of Options granted (i)
|
Total shares over which options are held (post award) |
Percentage of issued shares under option |
|
Iain Ross |
Executive Chairman |
14 July 2022 |
300,000 |
500,000 |
0.88% |
|
Catherine Isted |
Chief Financial Officer |
14 July 2022 |
650,000 |
1,114,136 |
1.95% |
|
Stefano Pluchino |
Chief Scientific Officer |
14 July 2022 |
100,000 |
100,000 |
0.18% |
|
Randolph Corteling |
VP of Research |
14 July 2022 |
500,000 |
500,000 |
0.88% |
|
Suzanne Hancock |
Head of Operations |
14 July 2022 |
250,000 |
349,326 |
0.61% |
ENDS
Enquiries:
|
ReNeuron |
||
|
Iain Ross, Chairman |
Via Walbrook PR |
|
|
Catherine Isted, Chief Financial Officer |
|
|
|
|
|
|
|
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking) |
+44 (0)20 3110 2000
|
|
|
|
|
|
|
Allenby Capital Limited (Joint Broker) |
+44 (0)20 3328 5656 |
|
|
James Reeve/George Payne (Corporate Finance) |
|
|
|
Stefano Aquilino (Sales & Corporate Broking) |
|
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About ReNeuron
ReNeuron is a UK based leader in proprietary stem cell derived exosome technologies, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.
ReNeuron's stem cell derived proprietary exosome technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
The Group has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-license both of these programmes in other territories.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to grant of share options to Directors and PDMRs)
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Iain Ross |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Executive Chairman |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
ReNeuron Group plc |
||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||
|
b) |
Nature of the transaction |
Grant of share options |
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information |
N/A |
||||
|
e) |
Date of the transaction |
14 July 2022 |
||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Catherine Isted |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Financial Officer |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
ReNeuron Group plc |
||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||
|
b) |
Nature of the transaction |
Grant of share options |
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information |
N/A |
||||
|
e) |
Date of the transaction |
14 July 2022 |
||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Stefano Pluchino |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Scientific Officer |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
ReNeuron Group plc |
||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||
|
b) |
Nature of the transaction |
Grant of share options |
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information |
N/A |
||||
|
e) |
Date of the transaction |
14 July 2022 |
||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Randolph Corteling |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
VP of Research |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
ReNeuron Group plc |
||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||
|
b) |
Nature of the transaction |
Grant of share options |
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information |
N/A |
||||
|
e) |
Date of the transaction |
14 July 2022 |
||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Suzanne Hancock |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Head of Operations |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
ReNeuron Group plc |
||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||
|
b) |
Nature of the transaction |
Grant of share options |
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information |
N/A |
||||
|
e) |
Date of the transaction |
14 July 2022 |
||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
